KEYNOTE 671 Trial Summary Introduction:The KEYNOTE 671 trial aimed to investigate the efficacy of perioperative pembrolizumab, an immune checkpoint inhibitor, in patients with resectable early-stage non–small-cell lung cancer (NSCLC). This randomized, double-blind, phase 3 trial assessed the benefits of neoadjuvant … Read More
Oncology
ZUMA 7 Trial: Axi-Cel Therapy- A New Hope for Patients with Early Relapsed or Refractory Large B-Cell Lymphoma
ZUMA 7 Trial Summary Patients with early relapsed or refractory large B-cell lymphoma often face poor prognoses after receiving first-line chemoimmunotherapy. However, a recent international, phase 3 trial has demonstrated promising results with the use of axicabtagene ciloleucel (axi-cel), an … Read More
SUNLIGHT Trial: Prolonging Survival for Advanced Colorectal Cancer Patients with Trifluridine–Tipiracil and Bevacizumab
The groundbreaking “SUNLIGHTTrial” recently highlighted the potential of the combined treatment of Trifluridine–Tipiracil (FTD–TPI) and Bevacizumab in extending the lifespan of patients with advanced colorectal cancer. The promising phase 3 study builds on prior research suggesting the efficacy of FTD–TPI … Read More
CATCH Trial Summary: Tinzaparin for VTE in Cancer
2015 CATCH TRIAL Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer phase 3, multinational, open-label, randomized controlled trial Objective: To assess the efficacy and safety of tinzaparin vs warfarin for treatment of acute, symptomatic … Read More
ALLIANCE Trial Summary: Axillary Dissection in Breast Cancer
2020 ALLIANCE TRIAL Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis Multicenter, phase 3, randomized controlled trial M Objective: To determine whether the 10-year overall survival … Read More
ALEX Trial Summary: Alectinib vs. Crizotinib in NSCLC
2017 ALEX TRIAL Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer international, open-label, randomised phase 3 trial Σ Objective: To compare alectinib (600 mg twice daily) with crizotinib in patients with previously untreated, advanced ALK-positive NSCLC, including those with … Read More
AGE Trial Summary: Mammogram Screening for Breast Cancer
AGE: Effect of mammographic screening from age 40 years on breast cancer mortality Multicenter, open label randomized comparative trial Objective: To assess if initiation of breast cancer screening with mammograms at age 40-41 reduces breast cancer mortality Women age 39-41 … Read More
IPASS Trial Summary: Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma
2009 IPASS TRIAL Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma phase 3, multicenter, open-label, parallel-group, randomised controlled trial d a Objective: To assess the effect of gefitinib as compared with carboplatin-paclitaxel for adenocarcinoma of the lung in nonsmokers or former light … Read More
TRICOP Trial Summary: Transfusion strategy in critically ill Oncologic patients
2017 2017 TRICOP TRIAL Liberal vs restrictive transfusion strategy in critically ill oncologic patients: The transfusion requirements in critically ill oncologic Single-center, randomized, double-blind controlled trial Objective: To assess whether a restrictive strategy of RBC transfusion reduces 28-day mortality when … Read More
VISION Trial Summary: Lutetium 177 PSMA 617 for Metastatic Prostate Cancer
2021 VISION TRIAL Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer Prospective, open-label, randomized, international, phase 3 trial Objective: To evaluate Lutetium-177 (177Lu)-PSMA-617 a radioligand therapy along with standard care in Prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer as compared … Read More